(NASDAQ: STOK) Stoke Therapeutics's forecast annual revenue growth rate of 71.48% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.01%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.06%.
Stoke Therapeutics's revenue in 2026 is $28,211,000.On average, 15 Wall Street analysts forecast STOK's revenue for 2026 to be $2,316,232,169, with the lowest STOK revenue forecast at $1,922,944,279, and the highest STOK revenue forecast at $2,733,327,940. On average, 15 Wall Street analysts forecast STOK's revenue for 2027 to be $3,018,041,424, with the lowest STOK revenue forecast at $237,163,128, and the highest STOK revenue forecast at $7,211,041,047.
In 2028, STOK is forecast to generate $10,593,853,228 in revenue, with the lowest revenue forecast at $5,243,228,068 and the highest revenue forecast at $15,859,711,865.